Kashiv Acquisition: Timeline, Synergies, and P&L Inflection Point Analysis

What “accretive” looks like in the filings: timeline and the P&L inflection point

1) Synergy timing: when the Kashiv economics start to flow through the P&L

Management frames the Kashiv deal as structured to be value-creating “from day 1” but also explicitly ties the earnings/accretion inflection to 2028. In the Q&A, they state the business will experience dilution next year until it becomes accretive in 2028.¹²³⁴⁵

Implied timeline (from the transcript wording):

• Day 1 / deal close period: Synergies are expected to start immediately (deal “structured to create value from day 1”).⁶
• 2027: Earnings are expected to be dilutive (or at least not fully accretive) versus a non-deal baseline, because management says dilution lasts “next year”.⁵
• 2028 (P&L inflection): The point at which the acquisition becomes accretive: “until it becomes accretive in 2028.”⁵
• 2030: The longer-run operating momentum is expected to be strong (revenues and EPS targets by 2030), reflecting that the full synergy/operating model should be largely embedded by then.⁷

2) Magnitude of the synergy stream tied to eliminating partner economics

The filings provide a direct quantification of cumulative financial synergies and explain one of the two key components:

• $400 million to $500 million cumulative financial synergies “over time.”⁴
• One key element is capturing full economics from partnered assets by eliminating milestones and profit-sharing obligations that existed under prior licensing deals.⁴

This is the “eliminated partner economics” mechanism the question is asking about; the excerpt does not give a month-by-month or year-by-year capture schedule for these eliminated obligations, but it does anchor:

• Total value to a cumulative range ($400m–$500m), and
• Nature of the benefit (milestone + profit share removal for partnered assets).⁴

3) When the economics become visible in earnings guidance (2027 vs 2028)

While the excerpt does not provide a bridge that isolates “full partner-economics capture” from other drivers, management does provide enough to pinpoint a P&L inflection in guidance:

• Management explicitly expects dilution in 2027 and accretion in 2028.⁵
• For 2027, management gave an adjusted EBITDA guidance of $820 million, which they discuss in relation to Street expectations and in the context of dealing with strategic dilution/accretion dynamics.⁵

They also frame 2026 and the base growth trajectory:

• Q1 2026 adjusted EBITDA $202 million, up 19%, and they describe continued ~10% adjusted EBITDA growth for the base business (with additional add-on from biosimilars).²
• Their operating narrative emphasizes that EBITDA expansion is a combination of base business growth and biosimilars add-on, rather than only synergy.²

So, the cleanest “P&L inflection” statement supported by the excerpt is:

• 2028 is the accretion year (after 2027 dilution), even though synergy and value creation are described as starting “from day 1.”⁵⁶

4) How management links “synergies” and “partner economics” to margin/earnings expansion

The excerpt connects partner economics elimination to “full economics” and specifically mentions:

• eliminating milestones and profit-sharing obligations from prior licensing deals.⁴

That kind of change is typically realized through:

• higher retained gross profit/EBITDA versus a model where profits are shared with a partner, and
• reduced pass-through/obligation costs tied to those milestones/profit-sharing mechanisms.

However, the excerpt does not quantify how much of the $400m–$500m cumulative synergies are specifically attributable to the eliminated milestone/profit-sharing items versus the other synergy component(s). It only identifies that this is one of two key elements.⁴

5) A sanity check using the company’s combined targets (trajectory confirmation, not a clean partition)

Management also provided “combined basis” performance targets, including by 2030:

• By 2030 revenues ~+$1.2 billion (~40%) over 2026, and EPS +~$0.70 (~70%) over 2026.⁷

This supports that the overall economics of the vertical integration + biosimilar operating build should be materially embedded by the early-2030 timeframe.⁷ But again, these targets do not provide a direct, isolated quantification of when the eliminated partner economics begin contributing to EPS/EBITDA in each year (the transcript instead gives the accretion timing: dilution 2027, accretive 2028).⁵

---

Direct answer (timeline + P&L inflection)

1. When do Kashiv synergies / eliminated partner economics become accretive in earnings?

• Management states the acquisition will be dilutive “next year” (i.e., 2027) until it becomes accretive in 2028.⁵
• The deal is also described as “structured to create value from day 1,” but accretion is explicitly tied to 2028.⁶⁵

2. How much value is tied specifically to eliminating partner economics?

• Management expects $400m–$500m cumulative financial synergies “over time.”⁴
• A key element is capturing full economics by eliminating milestones and profit-sharing obligations from prior licensing deals (i.e., eliminated partner economics).⁴

3. Can the filing quantify the exact year-by-year P&L inflection magnitude from partner-economics elimination (e.g., “X% EBITDA lift in 2027 from eliminated milestones”)?

• Not from the provided excerpts. The transcript quantifies total cumulative synergies and the mechanism, and separately states the accretion timing (2028), but it does not break out the partner-economics elimination contribution on a year-by-year P&L basis.⁴⁵

---

Key cited figures and dates (all from the excerpts)

• $400m–$500m cumulative financial synergies over time; includes eliminating milestones + profit-sharing obligations for partnered assets.⁴
• Value from day 1 (deal structuring language).⁶
• Dilution next year (2027) until accretive in 2028 (direct accretion timing statement).⁵
• Combined 2030 targets: revenues +~$1.2B (~40%) and EPS +~$0.70 (~70%) vs 2026.⁷
• 2027 adjusted EBITDA guidance of $820m (context for earnings trajectory during dilution/accretion transition).⁵

If you want, I can translate this into a simple “expected P&L realization curve” framework (still anchored only to what’s explicitly stated: dilution 2027, accretion 2028, cumulative synergies $400m–$500m, mechanism via eliminated partner obligations).